Back to Search
Start Over
Global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017
- Source :
- Lancet HIV, 6(12), e831-e859. Elsevier Limited, e859, e831, GBD 2017 HIV collaborators 2019, ' Global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2017, and forecasts to 2030, for 195 countries and territories : A systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017 ', The Lancet HIV, vol. 6, no. 12, pp. e831-e859 . https://doi.org/10.1016/S2352-3018(19)30196-1, The Lancet HIV, The Lens, The lancet London / HIV, 6(12):e831-e859, LANCET HIV, 6(12), E831-E859. Elsevier Ltd.
- Publication Year :
- 2019
-
Abstract
- BACKGROUND: Understanding the patterns of HIV/AIDS epidemics is crucial to tracking and monitoring the progress of prevention and control efforts in countries. We provide a comprehensive assessment of the levels and trends of HIV/AIDS incidence, prevalence, mortality, and coverage of antiretroviral therapy (ART) for 1980-2017 and forecast these estimates to 2030 for 195 countries and territories.METHODS: We determined a modelling strategy for each country on the basis of the availability and quality of data. For countries and territories with data from population-based seroprevalence surveys or antenatal care clinics, we estimated prevalence and incidence using an open-source version of the Estimation and Projection Package-a natural history model originally developed by the UNAIDS Reference Group on Estimates, Modelling, and Projections. For countries with cause-specific vital registration data, we corrected data for garbage coding (ie, deaths coded to an intermediate, immediate, or poorly defined cause) and HIV misclassification. We developed a process of cohort incidence bias adjustment to use information on survival and deaths recorded in vital registration to back-calculate HIV incidence. For countries without any representative data on HIV, we produced incidence estimates by pulling information from observed bias in the geographical region. We used a re-coded version of the Spectrum model (a cohort component model that uses rates of disease progression and HIV mortality on and off ART) to produce age-sex-specific incidence, prevalence, and mortality, and treatment coverage results for all countries, and forecast these measures to 2030 using Spectrum with inputs that were extended on the basis of past trends in treatment scale-up and new infections.FINDINGS: Global HIV mortality peaked in 2006 with 1·95 million deaths (95% uncertainty interval 1·87-2·04) and has since decreased to 0·95 million deaths (0·91-1·01) in 2017. New cases of HIV globally peaked in 1999 (3·16 million, 2·79-3·67) and since then have gradually decreased to 1·94 million (1·63-2·29) in 2017. These trends, along with ART scale-up, have globally resulted in increased prevalence, with 36·8 million (34·8-39·2) people living with HIV in 2017. Prevalence of HIV was highest in southern sub-Saharan Africa in 2017, and countries in the region had ART coverage ranging from 65·7% in Lesotho to 85·7% in eSwatini. Our forecasts showed that 54 countries will meet the UNAIDS target of 81% ART coverage by 2020 and 12 countries are on track to meet 90% ART coverage by 2030. Forecasted results estimate that few countries will meet the UNAIDS 2020 and 2030 mortality and incidence targets.INTERPRETATION: Despite progress in reducing HIV-related mortality over the past decade, slow decreases in incidence, combined with the current context of stagnated funding for related interventions, mean that many countries are not on track to reach the 2020 and 2030 global targets for reduction in incidence and mortality. With a growing population of people living with HIV, it will continue to be a major threat to public health for years to come. The pace of progress needs to be hastened by continuing to expand access to ART and increasing investments in proven HIV prevention initiatives that can be scaled up to have population-level impact.FUNDING: Bill & Melinda Gates Foundation, National Institute of Mental Health of the US National Institutes of Health (NIH), and the National Institute on Aging of the NIH.
- Subjects :
- 0301 basic medicine
A300 Clinical Medicine
Epidemiology
CITIES
HIV Infections
Mortalities
Global Burden of Disease
0302 clinical medicine
Risk Factors
Seroepidemiologic Studies
Cause of Death
Prevalences
Prevalence
Global health
LIFE EXPECTANCY
030212 general & internal medicine
10. No inequality
education.field_of_study
CHALLENGES
Incidence
Incidence (epidemiology)
Incidences
1. No poverty
MEN
3. Good health
AIDS
Infectious Diseases
Life Sciences & Biomedicine
GBD 2017 HIV collaborators
medicine.medical_specialty
Forecasts
Immunology
Population
Cause of Death/trends
UNITED-STATES
Context (language use)
History, 21st Century
03 medical and health sciences
SDG 3 - Good Health and Well-being
Acquired immunodeficiency syndrome (AIDS)
Virology
Environmental health
medicine
Humans
education
Global Burden of Disease/trends
Estimation
Science & Technology
SEX-SPECIFIC MORTALITY
business.industry
DISABILITY
Public health
HIV
coverage of antiretroviral therapy
History, 20th Century
medicine.disease
mortality
R1
PREVENTION
TRENDS
030112 virology
HIV Infections/mortality
3121 General medicine, internal medicine and other clinical medicine
Life expectancy
Human medicine
business
Forecasting
Subjects
Details
- Language :
- English
- ISSN :
- 23523018 and 24054704
- Database :
- OpenAIRE
- Journal :
- Lancet HIV, 6(12), e831-e859. Elsevier Limited, e859, e831, GBD 2017 HIV collaborators 2019, ' Global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2017, and forecasts to 2030, for 195 countries and territories : A systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017 ', The Lancet HIV, vol. 6, no. 12, pp. e831-e859 . https://doi.org/10.1016/S2352-3018(19)30196-1, The Lancet HIV, The Lens, The lancet London / HIV, 6(12):e831-e859, LANCET HIV, 6(12), E831-E859. Elsevier Ltd.
- Accession number :
- edsair.doi.dedup.....35626c0e25953cca70839c3befb0901f
- Full Text :
- https://doi.org/10.1016/S2352-3018(19)30196-1